Skip to content
RecruitingNot applicable

Ketamine in OCD: Efficacy and Effects on Stress and Cognition

NCT05577585 · KET-OCD · Medical University of Vienna

Recruiting
Status
Accepting participants
Not applicable
Phase
60
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Change of OCD symptoms (Y-BOCS)

    Measured over In total 7 YBOCS assessments will take place between week 1 and 5.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Primary diagnosis of obsessive-compulsive disorder * A score of 16 or higher on the Yale-Brown Obsessive Compulsive Scale and ability to provide written informed consent * At least one previous treatment for OCD Exclusion Criteria Experimental Group: * Any history of current or past psychotic disorder * A manic episode within the preceding three years * Current or unstable remitted substance abuse or dependence except nicotine * Pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception * Any current severe personality disorder except comorbid anankastic personality disorder * Morbus Raynaud * Inability to follow the study protocol or adhere to operational requirements * Current and unstable suicidality * Unstable hypertension * Untreated hyperthyroidism * Any unstable cardiovascular disease * Untreated disorders severely affecting the HPA-axis (M.Addison, M.Cushing) * Current pharmacological therapy severely affecting the HPA-axis like corticosteroids or ACTH Exclusion Criteria Treatment as Usual Group: * Any history of current or past psychotic disorder * A manic episode within the preceding three years * Current or unstable remitted substance abuse or dependence except nicotine * Any current severe personality disorder except comorbid anankastic personality disorder * Current and unstable suicidality

Where

1 study site

FacilityCityRegionCountry
Medical University of Vienna, Department of Psychiatry and PsychotherapyViennaState of ViennaAustria

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05577585 on ClinicalTrials.gov →

Last updated in the registry 2025-06-25. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits